Loading...
Loading...
Indian Pharmaceutical Exporter Β· #13 for Extract Β· $200.0K export value Β· DGFT Verified
Torrent Pharmaceuticals Limited is the #13 Indian exporter of Extract with $200.0K in export value and 4 verified shipments. Torrent Pharmaceuticals Limited holds a 1.6% market share in Extract exports across 1 countries. The company exports 43 pharmaceutical products worth $219.4M across 18 therapeutic categories.

| Country | Value | Shipments | Share |
|---|---|---|---|
| PHILIPPINES | $1.3M | 25 | 13.6% |
| UNITED ARAB EMIRATES | $1.2M | 260 | 12.9% |
| MYANMAR | $999.7K | 26 | 10.9% |
| SINGAPORE | $973.3K | 129 | 10.6% |
| UNITED STATES | $910.7K | 116 | 9.9% |
| MAURITIUS | $819.0K | 250 | 8.9% |
| NIGERIA | $816.6K | 58 | 8.9% |
| SYRIA | $413.1K | 15 | 4.5% |
| UZBEKISTAN | $344.3K | 23 | 3.7% |
| MALAYSIA | $300.6K | 78 | 3.3% |
India exports Extract to 109 countries. The top destination is PHILIPPINES (13.6%), followed by UNITED ARAB EMIRATES and MYANMAR.
| Buyer | Country | Value | Orders |
|---|---|---|---|
| REGENCY PHARMA LIMITED | MAURITIUS | $806.6K | 220 |
| MEDI MYANMAR GROUP LTD | MYANMAR | $550.0K | 11 |
| UNAHCO INC | PHILIPPINES | $500.0K | 10 |
| INOVA PHARMACEUTICALS(SINGAPORE) PT | SINGAPORE | $402.1K | 44 |
| NATURELLE LLC | UNITED ARAB EMIRATES | $300.2K | 25 |
India exported $6.6M worth of Extract through 2,147 shipments from 292 suppliers to 109 countries, serving 591 buyers globally. Torrent Pharmaceuticals Limited contributes $200.0K to this total, accounting for 1.6% of India's Extract exports.
Torrent Pharmaceuticals Limited's average Extract shipment value is $50.0K per consignment, based on 4 shipments totaling $200.0K.
Torrent Pharmaceuticals Limited ranks #13 among 292 Indian Extract exporters with a 1.6% market share. The top 3 exporters are DABUR INDIA LIMITED ($1.1M), PANACEA BIOTEC PHARMA LIMITED ($723.4K), J B CHEMICALS AND PHARMACEUTICALS LIMITED ($625.8K). Torrent Pharmaceuticals Limited processed 4 shipments to 1 destination countries.
What Torrent Pharmaceuticals Limited must comply with to export Extract to its top destination countries
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10β18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
Exporters ranked immediately above and below #13 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 14 | NIROGAM INDIA PRIVATE LIMITED | $216.2K | 79 | 1 | $2.7K |
| 15 | SUN PHARMACEUTICAL INDUSTRIES LIMITED | $211.3K | 18 | 1 | $11.7K |
| 13 | TORRENT PHARMACEUTICALS LIMITED β | $200.0K | 4 | 1 | $50.0K |
| 10 | OLIVE HEALTH CARE | $150.0K | 3 | 1 | $50.0K |
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 385 | 17.9% |
| SAHAR AIR CARGO ACC (INBOM4) | 238 | 11.1% |
| Bombay Air | 128 | 6.0% |
| DELHI AIR | 124 | 5.8% |
| NHAVA SHEVA SEA (INNSA1) | 117 | 5.4% |
| DELHI AIR CARGO ACC (INDEL4) | 101 | 4.7% |
| Delhi Air | 82 | 3.8% |
| BANGALORE ICD (INWFD6) | 74 | 3.4% |
The global pharmaceutical export landscape is currently navigating a series of geopolitical challenges that have direct implications for Indian exporters like Torrent Pharmaceuticals.
The ongoing Israel-Iran tensions have led to disruptions in the Red Sea shipping routes, a critical corridor for Indian pharmaceutical exports to the Middle East and North Africa (MENA) region. Maritime carriers have suspended bookings and rerouted shipments via the Cape of Good Hope, resulting in longer transit times and increased shipping costs. These disruptions are particularly concerning for time-sensitive pharmaceutical products, as extended lead times can affect product efficacy and shelf life. (pharmaceuticalcommerce.com)
In the United States, recent tariff policies have introduced additional complexities. The U.S. administration's imposition of broad tariffs on imports from over 60 countries, including India, has raised concerns about the competitiveness of Indian pharmaceutical products in the U.S. market. While health products have been exempted from these tariffs, the potential for future policy changes necessitates vigilance. (apnews.com)
The European Union's regulatory landscape is also evolving, with stringent compliance requirements under the Falsified Medicines Directive (FMD). Indian exporters must ensure adherence to these regulations to maintain market access. Non-compliance could result in significant market share losses in the EU, a key export destination for Torrent Pharmaceuticals.
Quality compliance remains a critical focus for Indian pharmaceutical exporters. The U.S. Food and Drug Administration (FDA) has intensified inspections of Indian manufacturing facilities, conducting over 200 inspections in 2023, with plans to increase this number in 2024. This heightened scrutiny underscores the importance of adhering to Good Manufacturing Practices (GMP) to ensure product quality and maintain export eligibility. (fact.net.in)
Torrent Pharmaceuticals has proactively addressed these regulatory challenges by investing in quality control systems and infrastructure. The company's commitment to compliance is evident in its consistent financial performance and sustained market presence. However, the broader Indian pharmaceutical sector continues to grapple with issues related to counterfeit drugs and quality concerns, which can impact the reputation of even compliant companies.
Torrent Pharmaceuticals Limited exports 43 products worth $219.4M. Beyond Extract, top products include Pantoprazole, Citalopram, Rosuvastatin, Escitalopram, Sertraline. View the complete Torrent Pharmaceuticals Limited profile for full portfolio analysis.
Latest developments and market context
Detailed market intelligence for Extract β including regulatory updates, trade policy changes, and competitive landscape analysis β will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records β the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Torrent Pharmaceuticals Limited's Extract exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Torrent Pharmaceuticals Limited
Full Company Profile β
43 products Β· $219.4M total trade Β· 18 categories
| DAVENBEN ENTERPRISES CORP |
| PHILIPPINES |
| $200.0K |
| 4 |
| ELBE PHARMA NIGERIA LIMITED | NIGERIA | $200.0K | 4 |
| DAILY - NEED INDUSTRIES LIMITED | NIGERIA | $194.7K | 4 |
| M/S DAVENBEN ENTERPRISES CORP | PHILIPPINES | $150.0K | 3 |
| MEDI MYANMAR GROUP LTD. | MYANMAR | $150.0K | 3 |
India's Extract is purchased by 591 buyers worldwide. The top buyer is REGENCY PHARMA LIMITED (MAURITIUS), followed by MEDI MYANMAR GROUP LTD and UNAHCO INC.
Torrent Pharmaceuticals Limited ranks #13 among 292 Indian Extract exporters. Average shipment value of $50.0K compared to the market average of $22.5K. The closest competitors by value are NIROGAM INDIA PRIVATE LIMITED and SUN PHARMACEUTICAL INDUSTRIES LIMITED.
Verify manufacturer licensing and export certifications with the official agencies above.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 109+ countries, 591+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Access shipment-level records, pricing trends, and buyer contacts for Torrent Pharmaceuticals Limited.
Request DemoView Pricing βTrade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Extract. For current shipment-level data, contact TransData Nexus.